For research use only. Not for therapeutic Use.
MT-4 blocks the TG2/FN complex at the interface between cancer cells and the tumor niche. MT-4 inhibits the adhesion of ovarian cancer (OC) cells to the peritoneum[1].
Pre-treatment with MT4 sensitizes ovarian cancer (OC) cells to traditional anticancer drug[1].
| Catalog Number | I018974 |
| CAS Number | 2327925-35-7 |
| Synonyms | N-[4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]phenyl]-2-phenylacetamide |
| Molecular Formula | C21H23N5O |
| Purity | ≥95% |
| InChI | InChI=1S/C21H23N5O/c1-15-13-19(26(2)3)25-21(22-15)24-18-11-9-17(10-12-18)23-20(27)14-16-7-5-4-6-8-16/h4-13H,14H2,1-3H3,(H,23,27)(H,22,24,25) |
| InChIKey | SKUUNAQXXGDUMF-UHFFFAOYSA-N |
| SMILES | CC1=CC(=NC(=N1)NC2=CC=C(C=C2)NC(=O)CC3=CC=CC=C3)N(C)C |
| Reference | [1]. Sima LE, et al. Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin. Mol Cancer Ther. 2019 Jun;18(6):1057-1068. |
